New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications
Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is genera...
Gespeichert in:
Veröffentlicht in: | Transplantation proceedings 2011-06, Vol.43 (5), p.1375-1394 |
---|---|
Hauptverfasser: | , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1394 |
---|---|
container_issue | 5 |
container_start_page | 1375 |
container_title | Transplantation proceedings |
container_volume | 43 |
creator | Kaposztas, Z Gyurus, E Kahan, B.D |
description | Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication. |
doi_str_mv | 10.1016/j.transproceed.2011.04.008 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_873493924</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0041134511006944</els_id><sourcerecordid>873493924</sourcerecordid><originalsourceid>FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</originalsourceid><addsrcrecordid>eNqNkk1v1DAQhi0EotuFv4AsJMSlCXbifPWAVLUUKlVdqezdcuwJ8jZrLx6nqBd-e53uViBOnGzPvPOO_XgIec9ZzhmvP23yGJTDXfAawOQF4zxnImesfUEWvG3KrKiL8iVZMCZ4xktRHZFjxA1L50KUr8lRweuuLJhYkN838CtbOYRIL6zqIQLSsyFCoLfg1EjXT51G5aKK1rvTWfXDebR4Qq-ctgachhN6a_GOXiodfZgT213aUu_oaorabyHFlDP0xt_DOGdHq5_s8A15NagR4e1hXZL15Zf1-bfsevX16vzsOtOiFjHr68GwQpiKi0ZzNbBKdFXNU4yZtlMtNEZ1RT90MLS65xU3g-77pm2Z6E1XlEvycW-bmP2cAKPcWtQwpneBn1AmZqIruwRnSU73Sh08YoBB7oLdqvAgOZMzfbmRf9OXM33JhEz0U_G7Q5up36bcc-kz7iT4cBAo1GockpG2-EcnBGtEN-su9jpITO4tBInazqSNDaCjNN7-330-_2OjR-sS-_EOHgA3fgrpj1FyiYVk8vs8L_O4cM5Y3QlRPgLUzb_W</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>873493924</pqid></control><display><type>article</type><title>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Kaposztas, Z ; Gyurus, E ; Kahan, B.D</creator><creatorcontrib>Kaposztas, Z ; Gyurus, E ; Kahan, B.D</creatorcontrib><description>Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.</description><identifier>ISSN: 0041-1345</identifier><identifier>EISSN: 1873-2623</identifier><identifier>DOI: 10.1016/j.transproceed.2011.04.008</identifier><identifier>PMID: 21693204</identifier><identifier>CODEN: TRPPA8</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Biological and medical sciences ; Diabetes Mellitus - epidemiology ; Diabetes Mellitus - etiology ; Diabetes. Impaired glucose tolerance ; Endocrine pancreas. Apud cells (diseases) ; Endocrinopathies ; Etiopathogenesis. Screening. Investigations. Target tissue resistance ; Fundamental and applied biological sciences. Psychology ; Fundamental immunology ; Humans ; Immunosuppressive Agents - administration & dosage ; Incidence ; Kidney Transplantation - adverse effects ; Medical sciences ; Risk Factors ; Surgery ; Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases ; Surgery of the urinary system ; Tissue, organ and graft immunology ; Treatment Outcome</subject><ispartof>Transplantation proceedings, 2011-06, Vol.43 (5), p.1375-1394</ispartof><rights>Elsevier Inc.</rights><rights>2011 Elsevier Inc.</rights><rights>2015 INIST-CNRS</rights><rights>Copyright © 2011 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</citedby><cites>FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.transproceed.2011.04.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24407494$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21693204$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Kaposztas, Z</creatorcontrib><creatorcontrib>Gyurus, E</creatorcontrib><creatorcontrib>Kahan, B.D</creatorcontrib><title>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</title><title>Transplantation proceedings</title><addtitle>Transplant Proc</addtitle><description>Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.</description><subject>Biological and medical sciences</subject><subject>Diabetes Mellitus - epidemiology</subject><subject>Diabetes Mellitus - etiology</subject><subject>Diabetes. Impaired glucose tolerance</subject><subject>Endocrine pancreas. Apud cells (diseases)</subject><subject>Endocrinopathies</subject><subject>Etiopathogenesis. Screening. Investigations. Target tissue resistance</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>Fundamental immunology</subject><subject>Humans</subject><subject>Immunosuppressive Agents - administration & dosage</subject><subject>Incidence</subject><subject>Kidney Transplantation - adverse effects</subject><subject>Medical sciences</subject><subject>Risk Factors</subject><subject>Surgery</subject><subject>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</subject><subject>Surgery of the urinary system</subject><subject>Tissue, organ and graft immunology</subject><subject>Treatment Outcome</subject><issn>0041-1345</issn><issn>1873-2623</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkk1v1DAQhi0EotuFv4AsJMSlCXbifPWAVLUUKlVdqezdcuwJ8jZrLx6nqBd-e53uViBOnGzPvPOO_XgIec9ZzhmvP23yGJTDXfAawOQF4zxnImesfUEWvG3KrKiL8iVZMCZ4xktRHZFjxA1L50KUr8lRweuuLJhYkN838CtbOYRIL6zqIQLSsyFCoLfg1EjXT51G5aKK1rvTWfXDebR4Qq-ctgachhN6a_GOXiodfZgT213aUu_oaorabyHFlDP0xt_DOGdHq5_s8A15NagR4e1hXZL15Zf1-bfsevX16vzsOtOiFjHr68GwQpiKi0ZzNbBKdFXNU4yZtlMtNEZ1RT90MLS65xU3g-77pm2Z6E1XlEvycW-bmP2cAKPcWtQwpneBn1AmZqIruwRnSU73Sh08YoBB7oLdqvAgOZMzfbmRf9OXM33JhEz0U_G7Q5up36bcc-kz7iT4cBAo1GockpG2-EcnBGtEN-su9jpITO4tBInazqSNDaCjNN7-330-_2OjR-sS-_EOHgA3fgrpj1FyiYVk8vs8L_O4cM5Y3QlRPgLUzb_W</recordid><startdate>20110601</startdate><enddate>20110601</enddate><creator>Kaposztas, Z</creator><creator>Gyurus, E</creator><creator>Kahan, B.D</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20110601</creationdate><title>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</title><author>Kaposztas, Z ; Gyurus, E ; Kahan, B.D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c464t-b6fd024d5147c1af0549561d020d89a8e7da92bf9ef8cb151dfcbb78804bd923</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Biological and medical sciences</topic><topic>Diabetes Mellitus - epidemiology</topic><topic>Diabetes Mellitus - etiology</topic><topic>Diabetes. Impaired glucose tolerance</topic><topic>Endocrine pancreas. Apud cells (diseases)</topic><topic>Endocrinopathies</topic><topic>Etiopathogenesis. Screening. Investigations. Target tissue resistance</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>Fundamental immunology</topic><topic>Humans</topic><topic>Immunosuppressive Agents - administration & dosage</topic><topic>Incidence</topic><topic>Kidney Transplantation - adverse effects</topic><topic>Medical sciences</topic><topic>Risk Factors</topic><topic>Surgery</topic><topic>Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases</topic><topic>Surgery of the urinary system</topic><topic>Tissue, organ and graft immunology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Kaposztas, Z</creatorcontrib><creatorcontrib>Gyurus, E</creatorcontrib><creatorcontrib>Kahan, B.D</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Transplantation proceedings</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Kaposztas, Z</au><au>Gyurus, E</au><au>Kahan, B.D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications</atitle><jtitle>Transplantation proceedings</jtitle><addtitle>Transplant Proc</addtitle><date>2011-06-01</date><risdate>2011</risdate><volume>43</volume><issue>5</issue><spage>1375</spage><epage>1394</epage><pages>1375-1394</pages><issn>0041-1345</issn><eissn>1873-2623</eissn><coden>TRPPA8</coden><abstract>Abstract Objective New-onset diabetes after transplantation (NODAT) is a multifactorial, complex metabolic disorder associated with impaired long-term graft function, reduced recipient survival, and increased risks of cardiovascular disease and infectious complications. The impact of NODAT is generally underestimated partly due to the inconsistent criteria that have been previously used for its diagnosis and to the generally short observation periods. The aim of this article was to review the recent literature on NODAT and to highlight the novel implications. Findings The 2010 American Diabetes Association guidelines provide useful, simplified criteria to unify the diagnosis including application of hemoglobin A1C levels. We sought to establish the impact of various modifiable and nonmodifiable risk factors. A vast number of papers have examined the effects of immunosuppressive medications on the development of NODAT: Neither calcineurin inhibitor nor sirolimus (SRL) or steroids seems to be innocent of contributing to it. Immunosuppressants account for 74% of the occurrence of NODAT. Among modifiable risk factors, obesity is independent and significant, with great prevalence in the population. In additional to lifestyle modifications, the role of bariatric surgery (BS) either before or after transplantation is highlighted herein as a strategy to reduce disease in the view of the results among overweight, nontransplanted patients. Summary Because of the strong association between high glucose values in the early posttransplant period and the development of NODAT, the condition must be recognized early after (or even before) transplantation by intensive screening. Patients at risk for NODAT must modify appropriate risk factors and particularly undergo pretransplant planning and/or posttransplant adjustment individualizing immunosuppressive therapy to mitigate the risk of this serious complication.</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>21693204</pmid><doi>10.1016/j.transproceed.2011.04.008</doi><tpages>20</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0041-1345 |
ispartof | Transplantation proceedings, 2011-06, Vol.43 (5), p.1375-1394 |
issn | 0041-1345 1873-2623 |
language | eng |
recordid | cdi_proquest_miscellaneous_873493924 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | Biological and medical sciences Diabetes Mellitus - epidemiology Diabetes Mellitus - etiology Diabetes. Impaired glucose tolerance Endocrine pancreas. Apud cells (diseases) Endocrinopathies Etiopathogenesis. Screening. Investigations. Target tissue resistance Fundamental and applied biological sciences. Psychology Fundamental immunology Humans Immunosuppressive Agents - administration & dosage Incidence Kidney Transplantation - adverse effects Medical sciences Risk Factors Surgery Surgery (general aspects). Transplantations, organ and tissue grafts. Graft diseases Surgery of the urinary system Tissue, organ and graft immunology Treatment Outcome |
title | New-Onset Diabetes After Renal Transplantation: Diagnosis, Incidence, Risk Factors, Impact on Outcomes, and Novel Implications |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T05%3A22%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New-Onset%20Diabetes%20After%20Renal%20Transplantation:%20Diagnosis,%20Incidence,%20Risk%20Factors,%20Impact%20on%20Outcomes,%20and%20Novel%20Implications&rft.jtitle=Transplantation%20proceedings&rft.au=Kaposztas,%20Z&rft.date=2011-06-01&rft.volume=43&rft.issue=5&rft.spage=1375&rft.epage=1394&rft.pages=1375-1394&rft.issn=0041-1345&rft.eissn=1873-2623&rft.coden=TRPPA8&rft_id=info:doi/10.1016/j.transproceed.2011.04.008&rft_dat=%3Cproquest_cross%3E873493924%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=873493924&rft_id=info:pmid/21693204&rft_els_id=S0041134511006944&rfr_iscdi=true |